PURPOSE - First-in-human phase 1 trial to determine the safety, pharmacokinetics, and anti-tumor activity of BIND-014, a novel, tumor PSMA-targeted nanoparticle containing docetaxel.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
EXPERIMENTAL DESIGN - Patients with advanced solid tumors received BIND-014 every three weeks (n=28) or weekly (n=27) with dose levels ranging from 3.
5 to 75 mg/m2 and 15 to 45 mg/m2, respectively.
RESULTS - BIND-014 was generally well tolerated with no unexpected toxicities. The most common drug-related toxicities (>20% of patients) on either schedule included neutropenia, fatigue, anemia, alopecia, and diarrhea. BIND-014 demonstrated a dose-linear pharmacokinetic profile distinct from docetaxel with prolonged persistence of docetaxel-encapsulated circulating nanoparticles. Of 52 patients evaluable for response, one had a complete response (cervical cancer on the every-three-week schedule) and five had partial responses (ampullary adenocarcinoma, non-small cell lung, and prostate cancers on the every-three-week schedule, and breast and gastroesophageal cancers on the weekly schedule). Responses were noted in both PSMA-detectable and undetectable tumors.
CONCLUSIONS - BIND-014 was generally well tolerated with predictable and manageable toxicity and a unique pharmacokinetic profile compared to conventional docetaxel. Clinical activity was noted in multiple tumor types. The recommended phase 2 dose of BIND-014 is 60 mg/m2 every three weeks or 40 mg/m2 weekly.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Feb 04 [Epub ahead of print]
Daniel Von Hoff, Monica M Mita, Ramesh K Ramanathan, Glen J Weiss, Alain C Mita, Patricia M LoRusso, Howard A Burris, Lowell L Hart, Susan C Low, Donald M Parsons, Stephen E Zale, Hagop Youssoufian, Jason Summa, Jasgit C Sachdev
Translational Genomic Research Institute and Virginia G. Piper Cancer Center. , Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center. , Hematology-Oncology, Mayo Clinic. , Clinical Research, Cancer Treatment Centers of America. , Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center. , Yale Cancer Center, Yale University. , Sarah Cannon Research Institute, Sarah Cannon Research Institute. , Hematology/Oncology, Florida Cancer Specialists. , R&D, BIND Therapeutics, Inc. , R&D, BIND Therapeutics, Inc. , R&D, BIND Therapeutics, Inc. , R&D, BIND Therapeutics, Inc. , R&D, BIND Therapeutics VGPCC Clinical Trials, TGen Clinical Research Service.